anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To produce amorphous calcium phosphate having excellent biocompatibility and having physical properties similar to those of bone tissue, by reacting a Ca salt with PO4, and filtering and drying the reaction product at a low temperature. CONSTITUTION:A reaction product obtained by the reaction of a Ca salt [e.g. Ca(NO3)2] with a PO4 salt [e.g. (NH4)3PO4] in an aqueous medium at 10-12pH is filtered at -10-0 deg.C, and is freeze-dried to obtain amorphous calcium phosphate [Ca3(PO4)2.xH2O]. The obtained amorphous calcium phosphate is added to an aqueous solution containing 10-60wt% curing agents selected from glycolic acid, lactic acid, glutamic acid, pantotheic acid, acrylic acid, their polymers, and a copolymer of the acids and &lt;=10wt% carboxylic acid. A bio-compatible composition suitable as a filler for filling the gap of a dental groove, a restoration material for alveolar bone, etc. can be produced by this process.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition that discharges toxins accumulated in the body more simply and effectively than a conventional one and is safe even if taken in a large amount.  &lt;P&gt;SOLUTION: The detox composition contains uronic acid as an active ingredient and has an action of discharging toxins from the body. Preferably uronic acid is monogalacturonic acid. Preferably toxins discharged from the body are heavy metals. The detox food and/or detox medicine contains any of the detox compositions.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PURPOSE:To provide an antitumor agent exhibiting cytocidal activity against cancer cells in vitro, and administrable continuously for a long period, by using 1alpha,24-dihydroxycholecalciferol as an active component. CONSTITUTION:1alpha,24-Dihydroxycholecalciferol of formula is used as an active component. The compound exhibits proliferation inhibiting effect and cytocidal effect in vitro to tumor cells such as K-562 cell derived from human leukemia, LICR-LON-HMy2 cell derived from human myeloma, etc. Furthermore, antitumor effect can be observed in the test using mouse and rat as the host. The LD50 is &gt;=2,000mug/kg for mouse by oral administration. Dose: 0.1-10,000mug, preferably 0.5-1,000mug daily for adult by parenteral or oral administration.
PROBLEM TO BE SOLVED: To obtain the subject agent, having activity to couple itself with σ-receptor in a peculiar manner, and useful for the treatment of mental disorders in which σ-receptor is involved, mainly mental diseases and schizophrenia, by incorporating a specific protopine type alkaloid. SOLUTION: This agent contains a compound shown by formula I [R1 to R8 are each H, hydroxy, a 1-6C alkoxy or the like, or the one forming methylenedioxy with the adjacent one; X is O or shown by formula II; R9 is a 1-6C alkyl, 2-6C alkenyl or 3-8C cycloalkyl; and (m), (n), (o) and (p) are each 0 to 5], e.g. the one shown by formula III. The compound shown by formula I is obtained by separating, by column chromatography, dried and methanol- extracted Corydalis impatients (Pall). Fish, a medicinal plant naturally growing in China&#39;s Szechwan Province, assessing the fractions for their σ-receptor coupling inhibiting activity, repeating separation and activity assessment procedures, and finally purifying and isolating it as the single component. It may also be obtained by known synthetic procedure. It is to be administered normally at 0.1 to 500 mg a day for an adult.
The invention relates to derivatives of the general formulae (I) and (II) to processes for the production thereof, to pharmaceutical preparations containing said compounds and/or physiologically compatible salts or solvates or prodrugs which can be produced therefrom as well as to the pharmaceutical use of said compounds, the salts or solvates thereof as adenosine receptor antagonists, in particular for the treatment of neurodegenerative disorders, e.g. stroke, amylotrophic lateral sclerosis, dementia, Alzheimer&#39;s disease, Parkinson&#39;s disease, ischemia/reperfusion injury, inflammation, and/or neurological disorder. The blockade of adenosine receptors could also be useful for other indications regarding the metabolism, e.g. diabetic retinopathy, diabetes mellitus, hyperbaric oxygen - induced retinopathy and/or obesity. Applications could also be the treatment of allergic diseases and autoimmune diseases, including mast cell degranulation, asthma, bronchoconstriction, pulmonary fibrosis, inflammatory or obstructive airways disease and/or chronic obstructive pulmonary disease (COPD). In addition, they could be used to treat cancer. The diseases associated with adenosine receptors are also diabetes, diarrhea, inflammatory bowel disease and/or gastrointestinal tract disorders. Adenosine receptor antagonists could be effective for treating a hepatic disease or condition for reducing fat deposition in the liver or fibrosis of the liver. The use of compounds of general formulae I or II can be associated with many applications e.g., scleroderm arthritis, atherosclerosis, urticaria, myocardial infarction, myocardial reperfusion after ischemia, vasodilation, hypertension, hypersensitivity, myocardial ischemia, heart attack and/or retinopathy of prematurity.
NEW MATERIAL:A compound expressed by formula I (A is expressed by formulas II, III or IV; X is ethylene or cis-vinylene; the bonds between the carbon atoms at the 13-, 14- and 15-positions are expressed by formula V when A is expressed by formula IIor III, and formula VI when A is expressed by formula IV; R is 1-12C straight chain or branched chain alkyl; R&lt;1&gt; is single bond, 1-5C straight chain or branched chain alkylene; R&lt;2&gt; is 1-8C straight chain or branched chain alkyl; etc.; the double bond between the carbon atoms at the 9- and 10-positions in formulas III and IV is Z; the double bond between carbon atoms at the 13- and 14-positions in formula V is E; the double bond between carbon atoms the 12- and 13-positions and the double bond between carbon atoms at the 14- and 15-positions in formula VI are E, Z or a mixture thereof) or a cyclodextrin clathrate compound thereof. EXAMPLE:2-Decarboxy-2-methyl-PGD2. USE:An antitumor agent having almost no pharmacological action unique to prostaglandin. PREPARATION:Compounds expressed by formulas VII and VIII (R&lt;3&gt; is tetrahydropyran-2-yl, etc.) are hydrolyzed under acidic conditions to give the compound expressed by formula I (A is expressed by formula II or III).
An isolated peptidic fragment of apolipoprotein E comprises at least 3 contiguous amino acids, Including glycosylated threonine 194, threonine 289, serine 94, or serine 76 of SEQ ID NO.: 1, or any combination of those. An antibody capable of binding to the isolated peptidic fragment. A method of detecting a naturally-occurring circulating atherogenic low-density lipoprotein in a plasma sample from an individual, comprising qualitatively and/or quantitatively detecting in a low-density lipoprotein that binds to the antibody. A method of assessing an individual&#39;s risk of ischemic heart disease and/or atherosclerosis comprises quantifying in a plasma sample from the individual an amount of apolipoprotein E comprising glycosylated threonine 194, threonine 289, serine 94 or serine 76 of SEQ ID NO.: 1, or any combination of those.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for evaluating the presence/absence or the degree of an edema by a simple and highly precise method, and to provide a method for evaluating the anti-edema action of a substance to be tested by a simple and highly precise method.  &lt;P&gt;SOLUTION: This evaluation method for edema measures the pinna sizes of mammals induced by a water intake or a water dosage. Also, the evaluation method for the anti-edema action of the substance to be tested includes the following four processes. In the process (i), an edema is induced to a mammal by dosing water. In the process (ii), the substance to be tested is dosed to the mammal before or after dosing water. In the process (iii), before dosing water, and after dosing water, and also, after dosing the substance to be tested, the size or the elasticity of the pinna of the mammal is measured. In the process (iv), the anti-edema action of the substance to be tested is evaluated from a difference between the measured value for the size or the elasticity of the pinna before dosing water, and the measured value of the size or the elasticity of the pinna after dosing water, and also after dosing the substance to be tested.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
Provided is an oxidative reduction potential (ORP) water solution that is stable for at least twenty-four hours and methods of using the solution. The present invention provides a method of preventing or treating a condition in a patient, which method comprises administering a therapeutically effective amount of the ORP water solution. Additionally provided is a method of treating impaired or damaged tissue, which method comprises contacting the tissue with a therapeutically effective amount of the ORP water solution. Further provided is a method of disinfecting a surface, which method comprises contacting the surface with an anti- infective amount of the ORP water solution. A process for producing an ORP water solution is also provided. ® KIPO &amp; WIPO 2007
PURPOSE:To obtain a shampoo composition capable of sufficiently exhibiting softness-imparting effect characteristic to a guanidine derivative without loosing foaming ability by compounding a nonionic surfactant, e.g. a sugar alcohol ester with a guanidine derivative. CONSTITUTION:At least one substance is selected from at least one kind of a nonionic surfactant group selected from a sugar alcohol ester of formula I (R&lt;1&gt; is a disaccharide residue; R&lt;2&gt; is an alkyl or an alkenyl; (n) is 1 or 2), an amine oxide of formula II (R&lt;3&gt; is a 8-18C alkyl or alkenyl), a polyoxyethylene alkyl ether of formula III (R&lt;4&gt; is a 8-20C alkyl or alkenyl; (m)=3-20) and a polyoxyethylene alkylphenyl ether of formula IV. The objective shampoo composition is composed of the selected nonionic surfactant in combination with a guanidine derivative. As the guanidine derivative, e.g. a compound of formula V or formula VI is selected. This shampoo composition can finish hair in a soft smooth touch.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to gynecology and physiotherapy, and can be used to treat chronic salpingo-oophoritis. To do this, rehabilitation of infection foci is carried out and enzyme preparation is used. As enzyme preparation, drug Fermencol is used, dissolved in preparation Solactin at a concentration of 0.1–0.2 mg/ml. &#34;Fermencol&#34; is administered by intravaginal electrophoresis at initial current strength of 0.1 mA, followed by increase in it during the session to 2 mA, focusing on patient&#39;s feelings, with maximum current density of not more than 0.1 mA/cm. At the same time as active electrode using vaginal electrode produced by LLC INISS-med. As a passive electrode, electrode with conductive tissue moistened with saline, located on lumbosacral area is used. Treatment session is carried out for 15 minutes, daily, in course of 15 days.EFFECT: method provides increase in effectiveness and accessibility of treatment, reduction in duration of treatment, achievement of stable remission, and improvement in reproductive function with no side effects.1 cl, 2 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a respiratory function sensor device reducing the cost.  &lt;P&gt;SOLUTION: This device is provided with a sensor chamber having a cylindrical part and a mouth piece part. The mouth piece is defined to direct an air flow in a tangential direction relative to the outside circular surface of the cylindrical part, and the cylindrical part is provided with a rotor rotating when a patient breathes the air into the mouth piece, in its inside. The rotor is provided with a central part along the rotating shaft and a rotor blade extending from the central part for receiving the tangential-direction air flow in the circular boundary of the cylindrical part. The central part, in its inside, is disposed with a bar magnet and generates a pulse according to a magnetic field changing when the rotor is rotated using a coil.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
This is a method for reproducing in vitro the RNA-dependent RNA polymerase activity associated with hepatitis C virus. The method is characterized in that sequences contained in NS5B are used in the reaction mixture. The terminal nucleotidyl transferase activity, a further property of the NS5B  protein, can also be reproduced using this method. The method takes advantage of the fact that the NS5B protein, either purified to apparent homogeneity or present in extracts of overproducing organisms, can catalyse the addition of ribonucleotides to the 3&#39;-termini of exogenous or endogenous RNA molecules.  The invention also relates to a composition of matter that comprises sequences contained in NS5B, and to the use of these compositions for the set up of an enzymatic test capable of selecting, for therapeutic purposes, compounds that inhibit the enzymatic activity associated with NS5B. The figure shows plasmids used in the method to produce hepatitis C virus RNA-dependent RNA polymerase and terminal nucleotidyl transferase in cultivated eukaryotic and prokaryotic cells.
PROBLEM TO BE SOLVED: To provide a new compound having excellent foaming power, foam stability and detergency even in hard water of high hardness, having low irritation and easiness to biodegradability to the hair and skin, and useful as a cleaning component having excellent use feeling. SOLUTION: This compound is expressed by formula I  R&lt;1&gt; is a 6-30C alkyl or alkenyl; R&lt;2&gt; is H or a group of formula II; A and B are each a 2-3C alkylene; R&lt;3&gt; is CH3 or CH2 COOM; (m) and (n) are each an average added mol number; M is H or a salt-forming cation}, e.g. amide ether sodium carboxylate. The compound of the formula I is obtained by condensing an α-halogenated carboxylic acid (e.g. α-chloropropionic acid, monochlorosuccinic acid, etc.), or its salt with a fatty acid alkanolamide or a polyoxyalkylene fatty acid alkanolamide in the presence of a basic catalyst (e.g. sodium hydroxide, potassium hydroxide, etc.), preferably in an amount of 0.1-5 wt.% of the compound or its salt at 60-100 deg.C for 2-6 hrs.
PURPOSE: To obtain a hair cosmetic which has excellent effect to give good feeling without oily or greasy hair touch and prevent hairs branching and damaging by using a specific acylated compound. CONSTITUTION: This hair cosmetic contains a salt of an acylated product obtained by condensation reaction between a fatty acid comprising &gt;=40% of a 20-32C branching fatty acid and a peptide derived from silk protein. The fatty acid is preferably lanolin fatty acid containing &gt;=20wt.% of anteiso branching fatty acid in the branching fatty acid. The peptide derived from the silk protein is preferably a hydrolyzate with a molecular weight of 300-600. The condensate is prepared, e.g. by acylating the silk protein with an acid chloride of the branching fatty acid at a pH of 8-9.5 and the product is an aqueous solution containing 30-40wt.% of the condensate in the solid state. The aqueous solution can used as a cosmetic, as it is or in the form of a powder after dried, and formulated to the cosmetic in an amount of 0.01-20wt.%.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a vaccine protective against meningococcal serogroup W135 and H. influenzae b type diseases.  &lt;P&gt;SOLUTION: Conjugated capsular saccharides derived from meningococcal serogroup C, serogroup W135 and serogroup Y are safe and immunogenic in humans when combined in a single dose. The conjugated antigens can stably be combined in a single aqueous dose without the need for lyophilization. Broad protection against serogroup B infection can be achieved by using a small number of defined polypeptide antigens. The polypeptide antigens can be combined with the saccharide antigens without losing the protective efficacy for any of the five serogroups. The efficacy of a serogroup W135 conjugate is enhanced by addition of protein antigens derived from a serogroup B strain. Addition of Hib (H. influenzae B type) conjugate to meningococcal conjugates enhances the overall activity against the meningococcal serogroup W135.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:To obtain a non-biological adsorbent useful for removing useless factor in plasma, by bonding a specific compound to a water-insoluble polymeric compound having hydroxyl group via a compound having &gt;=2 isocyanato groups in the molecule. CONSTITUTION:A compound of formula I (R1-R4 are H or 1-3C alkyl; n is 10-200) (e.g. polyethylene glycol) is bonded to a water-insoluble polymeric compound having hydroxyl group (e.g. agarose, cellulose and dextran) via a compound having &gt;=2 isocyanato groups in the molecule and expressed e.g. by formula I (R is 1-12C aliphatic chain or 6-15C aromatic chain) e.g. hexamethylene diisocyanate). The obtained adsorbent can effectively remove immunogloblin existing as a useless component in body fluid such as blood, IgG of patient of multiple myeloma and rejection reaction factor in organ transplantation.
PURPOSE:To obtain a preventive for dental caries having proliferation-inhibiting effect against Streptococcus mutans by extracting KANJU (rhizome of Dryopteris crassirhizoma) with methanol, fractionating the extract with a dialysis tube and using the obtained fraction having a specific molecular weight as an active component. CONSTITUTION:KANJU is extracted with methanol and the components soluble in a non-hydrophilic organic solvent are removed from the extract to obtain an aqueous solution. The solution is put into a dialysis tube having a fractional molecular weight of 1,000 and dialyzed with water. The inner liquid is put into a dialysis tube having a fractional molecular weight of 10,000 and dialyzed with water to fractionate into an inner liquid and an outer liquid and obtain NPF-87KAN-I having a molecular weight of 1,000-10,000 and NPF-87KAN-II having a molecular weight of &gt;=10,000. Both fractions are separately subjected to high-performance liquid chromatography and each fraction is separated into two fractions (IA having a molecular weight of 8,100, IB having a molecular weight of 4,900, IIA having a molecular weight of 12,800 and IIB having a molecular weight of 9,400). KAN-I is a mixture of IA and IB at a ratio of about 1:6 and KAN-II is a mixture of IIA and IIB at a ratio of about 1:4. Both fractions have comparable activities for the inhibition of the growth of Streptococcus mutans.
250,620. Freshie Co. , Inc., (Assignees of Mackenzie, K. A.). April 13, 1925, [Convention date]. Cleansing-compositions.-Small sheets of paper or similar fibrous material impregnated with cold cream are employed to remove dust &amp;c. from the skin. The sheets may be made up into book form and provided with a grease-proof cover, other sheets of absorbent material such as tissue paper being embodied in the book, if desired, to dry the skin. The sheets are impregnated by forcing the cold cream into the paper &amp;c, under pressure, so that the surface of the sheets remains free from the cream.
The invention relates to a formula of an external medicament for treating bedsore and a production process. The formula is characterized in that: the external medicament is prepared from the following raw materials in weight ratio: coptis root, rhubarb, red peony root, pearl powder, realgar powder, amber powder, calomel, (calcined) gypsum, (calcined) oyster, dried alum, dragon&#39;s blood, frankincense, myrrh, bezoar, borneol, licorice root, bee wax and sesame oil. The external medicament has the effects of strengthening body resistance and internal expression, activating blood, resolving toxin, removing corruption, promoting tissue regeneration, and promoting drop of necrotic tissues and healing of newly generated granulation. The external medicament is prepared by combining modern latest scientific achievements based on traditional Chinese medicament dialectic disease treatment. The invention aims to provide the external medicament for treating bedsore. The external medicament has the characteristics of accurate treatment effect, safety, convenience, no toxic or side effect and low cost.
Identified herein are different forms of bitter receptor genes that occur in different humans. These alleles are generated by numerous coding single nucleotide polymorphisms (cSNP&#39;s) that occur within the members of the T2R gene family. Some SNP&#39;s cause amino acid substitutions, while others introduce chain termination codons, rendering the allele non-functional. Differences in these genes are believed to have a large effect on those individuals&#39; sense of bitter taste, such that these individuals perceive the taste of bitter substances differently than the rest of the population. The ability to assay this allelic information is useful in the development of flavorings and flavor enhancers, as it can be used to define large groups and populations who perceive bitter tastes differently. This in turn allows the taste preferences of these groups to be addressed at the molecular level for the first time.
The invention takes the traditional medical health preserving and beautifying theory as guidance, and based on the achievement of modern process technology, the invention aims to innovate and help to solve a health preserving and beautifying scheme which is safe, effective, appropriate in cost, simple and convenient to take and treats based on syndrome differentiation. The &#39;Reozhou Huan Yan Jiaonang&#39; for harmonizing the physique is the main product. The prescription is composed of American ginseng, astragalus, angelica, radix rehmanniae, prepared rhubarb, frostbite, liquorice and other herbal medicines. It has the functions of benefiting qi, nourishing blood, relaxing the bowels, expelling toxin, dispersing blood stasis, reducing blood fat, promoting diuresis, eliminating turbidity, moistening skin, etc. Can be used for treating constipation, acne, and facial mottle due to deficiency of qi and blood, listlessness, and excessive toxic materials. The usage and dosage are as follows: 1-2 granules/time, 2 times/day, preferably moderate; or following the medical advice. Based on the main formula, the treatment can be carried out according to syndrome differentiation by adding or subtracting the medicinal flavors aiming at constitutional symptoms of yang deficiency, cold intolerance and yin deficiency and fire excess. It is worth repeatedly explaining that the health care tea has reasonable diet, good sleep, moisture retention, skin moistening and face refreshing. The heart is good, natural and reasonable, and risk is avoided. The product is used for removing turbidity and rejuvenating skin, is basically free of pain, damage and side effects, and is a health-care product integrating prevention, treatment and treatment.
PURPOSE:To obtain fucosterol in high yield, by separating algin from brown algae by extraction and filtration, treating the extraction residue with a mineral acid, and extracting the treated product with an organic solvent. CONSTITUTION:The residue left after the separation of algin from brown algae by extraction and filtration, is immersed in a mineral acid such as sulfuric acid, hydrochloric acid, etc. or in a solution of a &gt;=2-valent metallic salt (excluding Mg salt and Hg salt) (e.g. solution of calcium chloride). The immersed material is dehydrated, dried, and extracted with an organic solvent (e.g. dichloromethane, benzene, etc.) to obtain fucosterol as the extract.